Humana’s 2027 Medicare Advantage growth outlook is turning positive
Humana entered open enrollment with a very different problem than the one investors feared earlier this year. Early demand for 2027 Medicare Advantage coverage is running ahead of expectations, and the company now expects membership growth instead of the flat or negative trend it had previously prepared for.
CEO Jim Rechtin told investors that sign-ups have been more robust than Humana predicted, with recapture of members affected by plan exits coming in “particularly strong.” New enrollment is also running above plan. The shift is meaningful because it follows a year in which the insurer pared back its product offerings and braced for disruption from members forced to shop for replacement coverage.
One sentence captures the change in tone: Humana is no longer planning around contraction.
Broker channel changes are driving more of the gains than richer benefits
The membership surprise does not appear to be the result of unusually generous 2027 benefits. Rechtin said the outperformance is tied to a better distribution strategy, after Humana reshuffled its broker and channel partners. In practical terms, that means more seniors are being steered into Humana’s plans during enrollment, even as the insurer keeps its product design disciplined.
CFO Celeste Mellet added that turnover among smaller Medicare Advantage carriers could also be creating room for large national players to pick up members. That is a familiar pattern in a market where some plans are pulling back because of reimbursement pressure, rising medical costs, and growing uncertainty around the rules of the program. When smaller competitors leave, the largest carriers often inherit a share of displaced beneficiaries, especially if they still offer broad access and recognizable brand names.
Humana’s position is unusual because its 2026 product strategy had already produced more than 1 million new seniors in coverage, even after the company trimmed plans. Investors worried the influx could overwhelm margins if the new members used more services than expected. That burden did not fully materialize, but the insurer’s first half of the year was still relatively subdued compared with other publicly traded insurers that posted stronger operating surprises.
Margin recovery remains the central financial question
Medicare Advantage remains Humana’s core business, accounting for 40% of its membership and 80% of its premiums. That concentration makes any shift in enrollment especially important. It also explains why the insurer has had to work through a period of unusually tight pressure in a privatized Medicare market where utilization has stayed elevated since the coronavirus pandemic.
Mellet said any growth in 2027 should land in plans that generate higher profits, because Humana has already shut down lower-capital-return products. The company also says it has improved its product mix and price per margin, which was the top priority in this year’s bidding process. Those moves matter because Medicare Advantage profits depend not just on how many members join, but on whether the government’s payment formula adequately covers the cost of caring for them.
Humana declined to give a specific margin forecast for 2027, but executives said the company remains on track for meaningful recovery and still expects to reach a 3% Medicare Advantage margin in 2028. For investors, the key issue is whether growth can now coexist with improving economics rather than swallowing them.
Quality ratings could add a second revenue tailwind in 2028
A separate development may be even more valuable over time: Humana’s Medicare Advantage quality ratings surged for 2027. The share of members in plans rated 4 stars or higher rose from 41% in 2026 to 93% in 2027. In Medicare Advantage, star ratings drive bonus payments and other financial advantages, so the jump could translate into billions of dollars in extra payments in 2028.
For a company that suffered a major ratings collapse two years ago, the rebound is substantial. Rechtin said the latest results are close to the best Humana has ever achieved. Those higher scores do more than raise reimbursement. They also reinforce a broader commercial message to brokers, employers, and beneficiaries: the plans are now being presented as stronger products with better service quality and better clinical performance.
The earnings effect may arrive with a lag, but the strategic value is immediate. Higher ratings improve Humana’s negotiating position, strengthen its ability to attract members, and give management more room to invest without sacrificing shareholder returns.
A stronger enrollment cycle changes the pressure on 2027 guidance
Humana’s earlier concern was that the 2026 product exits would create a membership void large enough to weigh on earnings and delay recovery. About 600,000 seniors were affected by those exits, equal to 8% of the company’s 7.2 million Medicare Advantage members. That backdrop made the 2027 enrollment season unusually sensitive. A weak start would have reinforced fears that the insurer had miscalculated the long-term cost of its network changes. Instead, the early read points in the opposite direction.
The insurer still has to prove that these new members are profitable and that the gains are durable. Medicare Advantage economics can shift quickly if utilization rises, risk adjustment misses expectations, or policy changes compress reimbursement. Yet the near-term picture is clearly better than it was when the company was preparing for static or declining membership.
“We have just one headline today and that is that we are in a good place,” Rechtin said.
That confidence rests on a delicate balance: stronger enrollment, a better product mix, and a dramatic rebound in ratings, all against the background of a market that has forced many competitors to retreat. The remaining open question is not whether Humana can grow. It is whether the company can sustain that growth while converting it into the margin recovery it has promised investors for 2028.